Synthetic amylin curbs tendency to binge eat
Jun 8, 2007 - 4:00:00 PM
, Reviewed by: Dr. Himanshu Tyagi
|
|
|
"The findings of our clinical study further suggest that satiety hormones such as amylin can exert multiple effects on human eating behavior, such as reduced intake of highly-palatable foods and reduced binge eating tendency."
|
|
|
|
Pramlintide
|
|
Pramlintide is the synthetic form of amylin, a satiety hormone produced by the beta cells of the pancreas, which also produce insulin. Pramlintide is marketed in the U.S. by Amylin Pharmaceuticals, under the brand name Symlin, to treat diabetes and control blood sugar. Amylin is one of several hormones secreted when eating and is known to work in partnership with insulin to regulate blood sugar. Pramlintide is also under development as a potential drug for obesity.
|
|
By American Physiological Society,
[RxPG] The synthetic form of a hormone previously found to produce a feeling of fullness when eating and reduce body weight, also may help curb binge eating and the desire to eat high-fat foods and sweets. The findings on fast food consumption and binge eating tendencies are based on a 6-week research study of 88 obese individuals.
"Satiety hormones are commonly thought to control food intake by signaling to the brain when we are full," said Christian Weyer, M.D., the study's senior author and executive director of clinical research at Amylin Pharmaceuticals, Inc., in San Diego, Calif. "The findings of our clinical study further suggest that satiety hormones such as amylin can exert multiple effects on human eating behavior, such as reduced intake of highly-palatable foods and reduced binge eating tendency."
The study was carried out in 10 U.S. research sites and was reported by Steven R. Smith of the Pennington Biomedical Research Center in Baton Rouge, La.; John E. Blundell of the University of Leeds, United Kingdom; and Colleen Burns, Cinzia Ellero, Brock E. Schroeder, Nicole C. Kesty, Kim Chen, Amy E. Halseth, Cameron W. Lush and Christian Weyer, all of Amylin Pharmaceuticals.
Advertise in this space for $10 per month.
Contact us today.
|
 |
|
Subscribe to Bulimia Newsletter
|
|
|
|
About Dr. Himanshu Tyagi
|
This news story has been reviewed by Dr. Himanshu Tyagi before its publication on RxPG News website. Dr. Himanshu Tyagi, MBBS is the founder editor and manager for RxPG News. In this position he is responsible for content development and overall website and editorial management functions. His areas of special interest are psychological therapies and evidence based journalism.
RxPG News is committed to promotion and implementation of Evidence Based Medical Journalism in all channels of mass media including internet.
|
|
Feedback
|
For any corrections of factual information, to contact the editors or to send
any medical news or health news press releases, use
feedback form
|
Top of Page
|
